Cytokinetics Q3 Earnings Call Highlights
MarketBeat
Cytokinetics (NASDAQ:CYTK) reported $44.5 million in third-quarter net revenue from heart drug MYQORZO, up 76% from the prior quarter, as the company prepares regulatory submissions that could expand the treatment’s use.
President and CEO Robert Blum said the launch, nearly nine months in, continue
NASDAQ:CYTK